Multiple Myeloma

CLINICAL_TRIALS trial_result · 2025-05-30

Clinical Trial Update: Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors [NA]

Completed study evaluating a telehealth exercise program to improve physical function and reduce frailty in multiple myeloma survivors.

CLINICAL_TRIALS research · 2025-05-29

Clinical Trial Update: Study of 3D189 in Patients With Hematologic Malignancies [Phase 1]

Phase 1 study of 3D189 in hematologic malignancies is active but not recruiting.

CLINICAL_TRIALS trial_result · 2025-05-28

Clinical Trial Update: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma [Phase 1, Phase 2]

This clinical trial update reports termination of a Phase 1/2 study of EMB-06 for relapsed or refractory multiple myeloma.

CLINICAL_TRIALS trial_result · 2025-05-25

Clinical Trial Update: Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

Safety and efficacy study of OPC-415 in relapsed or refractory multiple myeloma is in Phase 1/2. The trial is currently ACTIVE_NOT_RECRUITIN…

CLINICAL_TRIALS trial_result · 2025-05-23

Clinical Trial Update: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]

Phase 2 trial evaluating the efficacy and safety of bb2121 in relapsed and refractory multiple myeloma has completed with results posted.

CLINICAL_TRIALS trial_result · 2025-05-23

Clinical Trial Update: A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

A Phase 1 trial evaluating the addition of recombinant human hyaluronidase (rHuPH20) to daratumumab for relapsed or refractory multiple myel…

CLINICAL_TRIALS research · 2025-05-23

Clinical Trial Update: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function [Phase 1]

This Phase 1 study investigates belantamab mafodotin as monotherapy in adults with multiple myeloma across varying degrees of renal impairme…

FDA approval · 2025-05-22

FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)

The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, expanding the label and/or indicat…

CLINICAL_TRIALS research · 2025-05-22

Clinical Trial Update: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies [Phase 1]

Phase 1 study of COM902, a TIGIT inhibitor, in patients with advanced malignancies is ongoing and currently not recruiting.

FDA approval · 2025-05-22

FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)

FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…

CLINICAL_TRIALS research · 2025-05-21

Clinical Trial Update: The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial

This clinical trial prospectively investigates whether counts of circulating progenitor cells (CPCs) measured by flow cytometry have prognos…

CLINICAL_TRIALS trial_result · 2025-05-20

Clinical Trial Update: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma [Phase 3]

This Phase 3 trial compares JNJ-68284528, a BCMA-directed CAR-T therapy, with pomalidomide-bortezomib-dexamethasone (PVd) or daratumumab-pom…

CLINICAL_TRIALS research · 2025-05-20

Clinical Trial Update: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]

This Clinical Trial Update describes a Phase 1 study evaluating CAR-GPRC5D cell therapy in patients with relapsed/refractory multiple myelom…

CLINICAL_TRIALS trial_result · 2025-05-20

Clinical Trial Update: A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

This clinical trial update notes the completion of a study evaluating the effectiveness of elranatamab in relapsed/refractory multiple myelo…

CLINICAL_TRIALS trial_result · 2025-05-18

Clinical Trial Update: Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma [Phase 1]

Phase 1 trial evaluating a triple combination of belantamab mafodotin, lenalidomide, and daratumumab for relapsed/refractory or previously u…

CLINICAL_TRIALS withdrawal · 2025-05-18

Clinical Trial Update: Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease [Phase 2]

A Phase 2 trial evaluating high-dose intravenous ascorbic acid in measurable solid tumors has been withdrawn, sponsored by Situs Cancer Rese…

CLINICAL_TRIALS research · 2025-05-18

Clinical Trial Update: Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) [Phase 2]

This clinical trial update indicates that a Phase 2 study of iberdomide in people with multiple myeloma who have previously undergone autolo…

CLINICAL_TRIALS trial_result · 2025-05-16

Clinical Trial Update: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

A Phase 1 trial evaluating eftozanermin alfa in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma ha…

CLINICAL_TRIALS trial_result · 2025-05-15

Clinical Trial Update: RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma [Phase 2]

Phase 2 trial of RAPA-201 T Cell Therapy for relapsed and refractory multiple myeloma has completed.

CLINICAL_TRIALS research · 2025-05-14

Clinical Trial Update: Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis [Phase 2]

This phase 2 study is evaluating the CAR-T therapy HBI0101 (NXC-201) in patients with multiple myeloma (refractory or relapsed) and light-ch…

CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study [Phase 1, Phase 2]

Phase 1/2 results for lenalidomide plus melphalan as a preparative regimen for autologous stem cell transplantation in relapsed multiple mye…

CLINICAL_TRIALS research · 2025-05-13

Clinical Trial Update: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma [Phase 2]

Phase 2 trial evaluating Iberdomide as maintenance therapy in adults with multiple myeloma; trial is active but not recruiting.

CLINICAL_TRIALS research · 2025-05-13

Clinical Trial Update: Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma [Phase 2]

Phase 2 clinical trial evaluating Mecapegfilgrastim with chemotherapy for peripheral blood stem cell mobilization in adults with multiple my…

CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: Fluoroquinolone Resistance Prevalence Study

A clinical trial investigating fluoroquinolone resistance prevalence was terminated.

EMA approval · 2025-05-12

EMA Authorised: Pomalidomide Zentiva (Pomalidomide) — Zentiva, k.s.

Pomalidomide Zentiva has been authorised for use in multiple myeloma by the EMA; it represents a generic version of pomalidomide.

Top drugs studied for this disease